Skip to content
Back to Blog
Bio
2026-05-117 min read17

KFDA Bio Rise-Up 1:1 Personalized Regulatory Consulting Strategy 2026

A complete guide to KFDA's 2026 Bio Rise-Up 1:1 personalized regulatory consulting program — covering the 5-stage lifecycle support, priority selection strategy, and KITIM's pre-application advisory linking regulatory consulting with government R&D funding.

KITIM Consulting Team

Overview of Bio Rise-Up Program

Starting in 2026, the Korean Ministry of Food and Drug Safety (KFDA) launches its 'Bio Rise-Up' 1:1 Personalized Regulatory Consulting system to dramatically reduce the regulatory burden on advanced biopharmaceutical developers. Moving away from fragmented after-the-fact consultations, the program represents a paradigm shift toward end-to-end accompaniment from early development through approval.

Why a Full-Lifecycle Companion Model?

  • Complexity of Advanced Biologics: Cell and gene therapies face rapidly evolving quality and clinical guidelines that single companies struggle to track
  • Reducing Development Failure: About 70% of domestic biotech ventures experience 6-9 month delays at the IND stage due to data deficiency requests
  • Global Competitiveness: Achieving regulatory alignment with the FDA and EMA from the outset is essential for parallel market entry
  • Expansion to 13 Specialist Consultants

    KFDA has newly recruited 13 senior reviewers and PhD-level experts from the Advanced Biopharmaceutical Division for 2026, establishing a dedicated single-consultant model per company across all development phases. The goal is to deliver 800+ consulting sessions to 200 firms annually.

    Scope and Stages of Consulting

    Five-Stage Lifecycle Support

  • Early Development: Candidate selection, mechanism of action assessment, regulatory classification
  • CMC (Quality): API and drug product quality control, GMP compliance, analytical method validation
  • Non-clinical: Safety study design, PK/toxicity evaluation, interspecies extrapolation
  • Clinical: IND submission, clinical trial design, patient recruitment, interim analysis
  • Approval Dossier Preparation: NDA/BLA package compilation, module-by-module drafting, review response
  • Product-Specific Consulting Tracks

  • Advanced Biologics Track: Antibodies, recombinant proteins, vaccines — biosimilar guidelines, comparability assessment
  • Regenerative Medicine Track: Stem cells, tissue engineering — Advanced Regenerative Bio Act compliance, long-term follow-up
  • Gene Therapy Track: AAV/lentiviral vectors, CAR-T — gene modification safety, environmental assessment, GMO regulations
  • Eligibility and Priority Selection Strategy

    Eligibility Requirements

  • Korean corporate entities developing advanced biopharmaceuticals (collaboration with research institutes/universities allowed)
  • Companies with pipelines between candidate selection and pre-approval stages
  • Priority bonus: Innovative Pharma certification, approved regenerative medicine clinical research, documented global expansion plans
  • Application Schedule and Method

  • Year-round Application: Submitted to the Advanced Biopharmaceutical Policy Division (quarterly priority selection meetings)
  • Pre-Application Meeting: 30-minute free pre-consultation available (development stage assessment)
  • Online Submission: Via the 'e-Pre-Consultation' system on the Drug Safety Country portal
  • Critical Preparation Materials

  • Stage-by-Stage Checklist: Candidate profile, mechanism hypothesis, competitor analysis
  • Draft Quality Documents: Manufacturing process flow, analytical method status, stability study plan
  • IND Preparation Package: Non-clinical summary, clinical design draft, patient recruitment plan
  • Prior Regulatory Reviews: FDA Pre-IND meeting records, EMA Scientific Advice outcomes (if available)
  • KITIM Utilization Guide

    KITIM provides pre-consultation and parallel advisory services that maximize the value of the Bio Rise-Up program. Because KFDA consulting focuses on regulatory compliance, internal document preparation and strategic planning require separate expert support.

    3-Stage KITIM Support Model

  • Pre-Application Document Advisory: Pipeline portfolio creation, regulatory adequacy diagnostics, identification of priority-selection bonus factors
  • Stage-by-Stage Regulatory Response Roadmap: 5-year milestone planning, KFDA response scenarios, deficiency-response playbooks
  • Parallel Government R&D Funding: Concurrent application to the Multi-Ministry Advanced Bio R&D Program (~KRW 120B annually), K-Bio Vaccine Fund, and Health & Medical Technology Promotion projects
  • KITIM Consulting Inquiry

    KITIM combines former KFDA advisors with biotech consulting experts and has supported approximately 30 bio companies annually in dual-tracking regulatory approval and R&D funding. If you need an integrated solution from Bio Rise-Up application preparation to government R&D linkage, contact KITIM. We offer a complimentary 1-hour pre-diagnostic to design a strategy tailored to your company.

    KFDABioRiseUpRegulatoryConsultingAdvancedBioBioSME

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.